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Abstract
Juvenile arthritis comprises a variety of chronic inflammatory diseases causing erosive arthritis in children, often 
progressing to disability. These children experience functional impairment due to joint and back pain, heel pain, 
swelling of joints and morning stiffness, contractures, pain, and anterior uveitis leading to blindness. As children who 
have juvenile arthritis reach adulthood, they face possible continuing disease activity, medication-associated 
morbidity, and life-long disability and risk for emotional and social dysfunction. In this article we will review the burden 
of juvenile arthritis for the patient and society and focus on the following areas: patient disability; visual outcome; other 
medical complications; physical activity; impact on HRQOL; emotional impact; pain and coping; ambulatory visits, 
hospitalizations and mortality; economic impact; burden on caregivers; transition issues; educational occupational 
outcomes, and sexuality.
The extent of impact on the various aspects of the patients', families' and society's functioning is clear from the existing 
literature. Juvenile arthritis imposes a significant burden on different spheres of the patients', caregivers' and family's 
life. In addition, it imposes a societal burden of significant health care costs and utilization. Juvenile arthritis affects 
health-related quality of life, physical function and visual outcome of children and impacts functioning in school and 
home. Effective, well-designed and appropriately tailored interventions are required to improve transitioning to adult 
care, encourage future vocation/occupation, enhance school function and minimize burden on costs.
Introduction
Juvenile Idiopathic Arthritis (JIA) is a chronic inflamma-
tory disease causing erosive arthritis in children, often
progressing to disability. JIA occurs in children of all
races, with annual incidence ranging from 0.008-0.226
per 1000 children, and prevalence from 0.07-4.01 per
1000 children [1]. A 2007 Centers for Disease Control
(CDC) study estimates that 294,000 U.S. children under
age 18 (or 1 in 250 children) have been diagnosed with
arthritis or another rheumatologic condition [2]. The
national direct costs in 1989 are estimated at $285 million
in the US for children with arthritis [3].
One of the most frequently occurring pediatric rheu-
matic diseases, JIA, impacts bio-psychosocial aspects of
patients and families necessitating careful diagnosis and
initiation of appropriate treatment. JIA is comprised of
the following seven categories as per the ILAR (Interna-
tional League of Associations of Rheumatology) classifi-
cation [4]:1) Oligoarticular onset JIA also termed as
Pauciarticular onset JIA (PaJIA); 2) Polyarticular onset
JIA (PoJIA RF+) with positive results on testing for Rheu-
matoid Factor (RF); 3) Polyarticular onset JIA (PoJIA RF-)
with negative results on testing for RF; 4) Systemic arthri-
tis (SoJIA); 5) Psoriatic arthritis JIA; 6) Enthesitis-related
arthritis; and 7) Other arthritis undefined by above men-
tioned criteria [4]. Each subtype is associated with spe-
cific complications and disabilities. Early disease
recognition and institution of appropriate therapy is criti-
cal to improve the clinical outcome.
As children who have JIA reach adulthood, they face
possible continuing disease activity, medication-associ-
ated morbidity, life-long disability and risk for emotional
and social dysfunction. Children with JIA with uveitis
experience additional visual problems leading to disabil-
ity. In this article we will review the burden of JIA for the
patient and society focusing on the following areas:
patient disability; visual outcome; other medical compli-
cations; physical activity; impact on health-related quality
of life (HRQOL); emotional impact; pain and coping;
ambulatory visits, hospitalizations and mortality; eco-
nomic impact; burden on caregivers; transition issues;
educational occupational outcomes; and sexuality. We
will discuss the above topics under the three following
headings: Physical Disability, Impact on HRQOL and
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the context of childhood arthritis were selected using
MEDLINE search technique.
JIA comprises a heterogeneous group of diseases with
distinct subtypes and all these subtypes have different
phenotypes, course and prognoses. Although, we have
included all the subtypes of JIA, we stress here that we
need further studies in the following areas in each of the
subtype. Further, not all the articles have exclusively used
the ILAR system of classification. We have several studies




Several studies have elucidated the extent of disability
associated with JIA. Solari et al explored the disease out-
comes of a cross-sectional sample of 310 children with
JIA for at least 5 years and found that about one-fifth had
moderate to severe disability, 3.6% were in Steinbrocker
class III-IV, and about 10% had major impairment in
HRQOL [5]. One-third of the patients had damage in at
least one joint or joint group and one-fourth showed
extraarticular damage. Thirty-five percent of the 150
patients having a wrist radiograph had significant struc-
tural damage, while 9% had growth retardation [5]. Since
a considerable proportion of the patients had active dis-
ease and attendant disability, impaired function, and
damage, the cumulative burden will impose a significant
load on health care resources.
Russo et al studied 47 patients with SOJIA with at least
2 years of disease and found that 43% patients exhibited
damage (38% with articular and 19% with extraarticular
damage) [6]. The chief determinants of damage were cer-
vical spine arthritis and corticosteroid usage in the first 6
months of the disease course. Further, the damage scores
correlated with number of joints with limited motion,
and functional disability [6]. In another study of 89 JIA
patients, almost two-thirds of patients had articular dam-
age and one third had extra-articular damage [7]. Growth
failure was the most common extra-articular manifesta-
tion. Juvenile arthritis damage index (JADI)-A (a measure
or articular damage) correlated with the following vari-
ables: (a) radiological damage; (b) childhood health
assessment questionnaire (CHAQ); (c) JADI-E (measure
of extraarticular damage); (d) disease; and (e) loss of edu-
cation years due to disease; and (f ) measures of disease
activity [7].
In a longitudinal analysis, 227 patients with JIA were
given functional ability questionnaires to complete [8].
The total number of completed questionnaires was 1,356.
The interval between first and last questionnaire admin-
istration was 949.7 patient years. Three longitudinal pat-
terns were observed. First pattern was the absence of
disability was found in 27.8% of patients and persistently
moderate disability in 3.5%. Second pattern was the find-
ing of a steady improvement (22.9%) or deterioration
(5.7%) in disability over time. The third pattern was the
finding of a fluctuating course of disability, with deterio-
ration and improvement (40.1% of patients). The chief
determinants of poor functional ability were younger age
at disease onset and a greater restricted joint count. A
wide within-patient and between-patient variability in
the longitudinal course of functional disability was found.
Children with early disease onset and a greater number of
restricted joints had the highest risk of developing long-
term physical disability [8].
A Mexican cross-sectional study examined the impact
of disability on the quality of life in 32 Mexican adults
with polyarticular course JIA (mean age 26 years) and
juvenile ankylosing spondylitis (JAS) (mean age 27 years)
[9]. A significant proportion of patients with JIA (65%)
and JAS (50%) had Global Functional Status (GFS) class
III/IV. Thirty-two percent of JIA patients had a score
greater than 1.5 when assessed by the Health Assessment
Questionnaire-disability index (HAQ-DI). Ninety-two
percent of the JAS patients had a score greater than 5
when examined by the Bath Ankylosing Spondylitis Func-
tional Index (BASFI). A higher BASFI score indicates
worse functional ability. All patients had lower scores for
all physical and mental subscales of the medical out-
comes study 36-item short-form health survey (SF-36)
when compared with Mexican population scores (p <
0.005). But health status did not differ between the
patients with JIA and JAS. EQ-5D, a quality of life scale
showed impairment in all dimensions for JIA and JAS
patients. The primary determinant of quality of life
(QOL) as measured by SF 36 questionnaire was the GFS
score. These results suggest that functional status signifi-
cantly impairs HRQOL in adults with JIA and JAS [9].
The above studies from 2007-2008 represent the transi-
tion period to biologic agents and several of these
patients were probably on methotrexate and non-biologic
agents. As biologic agents are gaining popularity, next
decade may present different results such as lower level of
disability and increased functional capacity.
Visual outcome
Children with PaJIA, PoJIA, psoriatic arthritis and
enthesitis-related arthritis are all at risk for uveitis with
potential for visual loss. In order to examine the long-
term outcome of JIA-associated uveitis, Ozdal et al stud-
ied 18 adults with JIA-associated uveitis with mean dura-
tion of 21 years [10]. The mean age of the patients at last
examination was 30 years and the mean age at onset of
arthritis and uveitis was 5 and 9 years respectively. All
patients had eyes with at least one ocular complication
[10]. Final visual acuity was impaired in 40%, poor in 20%,
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eyes were either visually handicapped or totally blind.
Most eyes endured at least one surgical procedure. All
patients were on topically and systemic NSAID; and 61%
of patients were on an immunosuppressive agent [10].
Kump et al conducted a retrospective review and found
that of 269 children with uveitic syndromes, 89 (33%) had
JIA-associated uveitis, and it was bilateral in most (76
children) [11]. Mean age of onset of uveitis was about 6
years and mean follow up was about 3 years. Children
with JIA-associated uveitis developed the following com-
plications in the course of their disease: cataracts (64%);
increased intraocular pressure (20%); developed band
keratopathy (46%); and posterior synechiae (58%). The
treatment regimen was as follows: single-/two-/three- or
greater immunomodulating agents (73%); nonsteroidal
anti-inflammatory agents alone or in combination with
immunomodulating agents (40%); and topical and/or sys-
temic steroids (21%). Using mixed-models linear regres-
sion, improvement in visual acuity was not found to be
statistically significant [11].
A more recent retrospective chart review of a subset of
1,081 JIA patients under 18 years with at least one year
follow-up at a single center revealed the following: 13%
developed uveitis after a mean follow-up of 6 years; com-
plications related to uveitis were observed in 37% of
cases; and 15% with uveitis underwent a total of 62 ocular
surgeries [12]. Good visual acuity was found in 91% of
eyes; impaired visual acuity in 6 eyes (3%), and blindness
in 10 eyes (6%). Children with JIA achieved good visual
outcome despite uveitic complications [12]. Children
with JIA with uveitis on topical steroids often require cat-
aract surgery. While the surgery improves their outcomes
significantly [13], it imposes a financial burden. Another
recent long-term study of 55 patients with JIA-associated
uveitis showed 42% of patients developed cataracts at 7
years and in 51% at 24 years [14]. Further, 5% developed
glaucoma 7 years and 22% at 24 years [14]. After 24 years,
almost one-half of the patients (27) still had active uveitis
[14]. These studies reflect the blinding potential of JIA-
associated uveitis. The complications of uveitis are signif-
icant including chronic medication use and physician
appointments, surgery, and visual handicap, all of which
result in impaired quality of life.
Physical activity
Lelieveld et al found that total energy expenditure, activ-
ity-related energy expenditure, and physical activity levels
were significantly lower in the 30 adolescents with JIA
compared to 106 controls [15]. Adolescents with JIA
spent a greater percentage of time in bed and less time on
moderate to vigorous physical activity. Only 23% of the
JIA patients met public health guidelines on physical
activity compared with 66% in the control group [15].
Other Related Medical Complications
Podiatry
Foot problems are prevalent in patients with JIA (over
90%) [16] (reviewed in). In one study of 30 patients with
JIA, 63% reported some foot impairment; 53% reported
foot-related activity limitation; and participation restric-
tion was endorsed by 60%. Ten children (one-third)
sought podiatry care. Although immunomodulating and
biologic therapies are increasingly used, foot-related
impairment is significant and requires podiatry care [16].
Gastrointestinal symptoms related to therapy
While performing the initial validation of Gastrointesti-
nal Symptom Scale for Kids (GISSK) in children with
juvenile rheumatoid arthritis (JRA), Brunner et al found
that gastrointestinal (GI) symptoms were present in the
majority of the patients with JRA (58%) [17]. Patients
with moderate or severe GI symptoms requiring
advanced therapies were associated with lower HRQOL
[17].
Amyloidosis
In a Finnish study, patient registers and amyloidosis
biopsy files from 1976-2003 from the Center of inflam-
matory joint disorders were examined for amyloidosis in
patients under age 19 years [18]. Additionally, medical
records were reviewed, and patients were interviewed by
telephone. Death certificates were reviewed to determine
cause. Twenty-four patients under age 19 years with
biopsy-proven amyloidosis were found. Authors found
the 5-year survival rate of the series to be 87.5% (95% CI
75% to 100%), and 10-year survival to be 75% (95% CI
54% to 92%). Ten out of the 24 died during a mean follow-
up of 15.4 years. The chief cause of death was related to
JIA in 9 patients. Patients treated with corticosteroids
alone after the diagnosis of amyloidosis had a higher mor-
tality than those taking disease modifying anti-rheumatic
drugs (p = 0.001). Of the 14 patients who were alive, 12
had normal renal function (3 of them had undergone
renal transplantation), one had renal insufficiency, and
one had proteinuria. All the 14 patients had completed at
least the 9 years of mandatory education, and 4 had aca-
demic degrees. Two female patients had delivered healthy
children. This Finnish study suggests that the outcome of
JIA-associated amyloidosis is poor overall [18].
Impact on HRQOL, Pain and Coping
Impact on HRQOL
Several studies have examined the impact of JIA on
HRQOL. Patients with JIA and reactive arthritis had
lower HRQOL compared to normative data [19]. Chil-
dren had lower HRQOL in the domain of self-esteem;
adolescents had lower HRQOL in the areas of physical
well-being and total QOL. About one-fifth of the cohort
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social isolation and depression and/or anxiety. Functional
impairment impacted HRQOL and behavioral issues.
The chief determinants for poor HRQOL were functional
limitations, social isolation and depression and/or anxiety
[19]. Shaw et al examined the HRQOL in 308 adolescents
and found that HRQOL of adolescents with JIA was less
than optimal, particularly in the domains of gross motor
and systemic functioning [20]. In another cohort of 88
JIA patients, variables "limitation of mobility" and "pain"
showed the robust association with HRQOL, implying
that HRQOL is directly influenced by the consequences
of the illness [21]. Sixty children with JIA and/or their
parents/proxies participated in a recent study. Subjects
with active disease had lower scores on the Pediatric
Quality of Life Inventory (PedsQL™) Generic Core Scales
and the PedsQL™ Rheumatology Module than those with
inactive disease. Participants also reported more fatigue
compared to controls regardless of disease activity status
[22].
Another study assessing 80 subjects with JIA reported
that children with polyarticular and systemic subtypes
had worse fine and gross motor function, greater psycho-
social impact and greater number of symptoms compared
to patients with persistent oligoarticular type [23].
HRQOL was decreased in adolescents and worsened with
delay in diagnosis. The decrease of HRQOL was linked to
disease activity, disability index (measured by CHAQ)
and presence of hip involvement. This study implies that
JIA has substantial adverse impact on HRQOL of
patients, principally adolescents with polyarticular and
systemic subtypes. The chief predictors of poor HRQOL
are disease duration, disability score (CHAQ) and pain
[23].
In a multinational, cross-sectional study, HRQOL was
assessed in 3,324 JIA patients using the Child Health
Questionnaire (CHQ) and compared to HRQOL of 3,315
healthy children [24]. At the time of the study visit, JIA
patients were younger (mean age 10 years) than the
healthy controls (mean age 11 years). There were more
girls in the JIA group compared to controls; however,
there was no difference between the physical and psycho-
social scores between the healthy males and females. The
mean physical and psychosocial summary scores of the
CHQ were significantly lower in patients with JIA than in
healthy children, with the physical well-being domain
being most affected. Patients with persistent oligoarthri-
tis had better HRQOL compared to other subtypes; and
HRQOL was similar in patients with systemic arthritis,
polyarthritis, and extended oligoarthritis. Poor physical
function (CHAQ score > 1) and increased pain intensity
(pain intensity rating > 3.4 cm) on a 10-cm visual analog
scale were the strongest predictors of poorer HRQOL in
the physical and psychosocial domains, respectively.
Clearly, HRQOL of children with JIA is greatly impacted
in the area of physical function. Physical well-being was
influenced by the extent of functional disability, and pain
intensity affected psychosocial health [24]. These studies
confirm that these patients have significantly impaired
HRQOL compared to healthy children and the physical
function domain is primarily involved.
Impact on mental health
While impact of JIA on physical function and global
HRQOL is well characterized, there are fewer studies that
address the emotional impact of JIA. Mullick et al evalu-
ated 40 subjects (24 boys) aged 10-18 years with JIA for at
least one year and 40- age and sex-matched healthy con-
trols were included as controls [25]. The frequency of
psychiatric disorders (based on ICD-10 clinical diagnoses
of multiaxial classification of child and adolescent psychi-
atric disorders) was significantly higher in JIA (35%) than
in the control group (12.5%). The increased length of ill-
ness was linked with a higher percentage of cases with
psychiatric disorders. In the JIA group, the frequencies of
the various diagnoses were as follows: depressive disorder
(15%), somatoform disorder (12.5%), adjustment disorder
(5%), and mixed anxiety and depressive disorder (2.5%).
In addition, the JIA group with psychiatric problems had
substantially higher stressors, perceived difficulties, dis-
tress, social impairment, and burden for caregivers were
reported in the JIA group with psychiatric morbidity. The
presence of psychiatric disorders was related to consider-
able difficulties with learning, peer relationships, and lei-
sure activities. This study suggests that early recognition
of psychiatric illness and management might improve the
outcome in children with JIA [25].
Vuorimaa et al examined the relationship between
arthritis in 145 children and self-efficacy, trait-anxiety,
depression, clinical state of the disease (pain, disability,
number of somatic complaints and active joints) and age
of the child [26]. Interestingly, clinical classification of
disease activity and severity was not directly linked to
depression and trait-anxiety in children with JIA. It was
self-efficacy that corresponded with less pain and somatic
complaints [26].
Ding et al investigated the psychological functioning of
60 children with polyarticular joint disease and its associ-
ation with disease activity and disability. The authors
found that all facets of psychological function (depres-
sion, anxiety and behavior) correlated moderately with
physical function. Poor psychological outcome was
linked with more severe physical disability, but not with
the extent of disease activity [27]. Clearly, more studies
are needed to determine the extent and pattern of emo-
tional factors on the symptoms, functioning and HRQOL
of patients with JIA.
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Thastum et al examined whether the pain-specific beliefs
and coping strategies of JIA patients independently pre-
dicted their reported pain [28]. Results from this study
supported a model of pain experience in patients with JIA
where psychological factors are strongly influential. Their
findings suggested that behavioral interventions may be
highly relevant in patients who experience pain that
appears out of proportion to the disease activity [28].
Sawyer et al examined the relationship between
HRQOL, the experience of pain and pain coping strate-
gies in 59 children (8-18 years) with JIA and their parents
[29]. Parents stated significantly lower HRQOL scores
compared to children on five of the eight PedsQL™ scales
rating children's HRQOL. The authors found a notable
inverse linkage between pain levels and the PedsQL™
scores assessing children's physical, emotional and social
functioning for both children and parents. They also
found a significant inverse relationship between scores on
numerous pain coping scales and scores on the PedsQL™
scales. The authors concluded that intensity and pain
coping strategies have a significant and independent rela-
tionship with several domains of HRQOL. Further, par-
ents and children have differing views of the nature of
these relationships, highlighting the need for obtaining
child and parent reports [29].
Burden on caregivers
Parents often have to miss days of work to care for their
sick children. Parents have to bring children to their phy-
sician's regular appointments, and additional urgent and
emergency room visits during disease flares or infections
(since they are often immunocompromised). In addition,
parents have to schedule appointments to obtain labora-
tory tests and imaging studies. Parents have to frequently
refill one or more medications. These activities can result
in significant emotional, financial and logistical burden
for the parents. Bruns et al examined the QOL and dis-
ease burden of primary caregivers of 70 patients with JIA
[30]. They used the CHAQ, SF-36, and the psychiatric
screening questionnaire (SRQ-20). Burden of disease on
the caregivers was measured by the caregiver burden
scale (CB Scale). Majority of the caregivers were married
mothers with an average age of 37 years; most of them
had low education and socioeconomic status. Psychoe-
motional disorders were identified in one-third of the
caregivers. Items on pain and mental health from the SF-
36 questionnaire were the most impacted. The CB Scale
correlated with the SRQ-20, number of limited joints,
number of visits, family income, and mental health, emo-
tional aspects, social aspects, vitality and general health
state of the SF-36. SRQ-20 was the most critical determi-
nant of CB Scale and of the domains of pain and mental
health of the SF-36 questionnaire. Patients' emotional sta-
tus (rather than the physical status) likely contributes a
greater load on the caregivers [30].
Transition issues
In order to delineate the transitional care workload of a
multicentre cohort of adolescents with juvenile idiopathic
arthritis (JIA) including disease, self-advocacy and voca-
tional issued, Shaw et al collected data using question-
naires completed by clinicians, patients and parents in 10
UK pediatric rheumatology centers [31]. Patients with a
confirmed diagnosis of JIA for at least 6 months and an
age of 11, 14 or 17 yrs were included. 308 adolescents
with JIA and 303 parents/guardians participated and of
these, 19.5% had persistent oligoarthritis. Despite their
upcoming transfer to adult care, the following transi-
tional issues were prevalent in the 17-yr-olds:
Over half the patients were accompanied by their par-
ents during their rheumatology appointment; one-
fifth of the patients were not self-medicating; two-
thirds had not had intra-articular injections under 
local anesthetic; and one-seventh had not received 
counseling related to their future careers.
Over half of the 17 yr-olds had moderate to severe 
functional disability. Sixty-eight percent were still on 
disease-modifying anti-rheumatic drugs and, experi-
enced increased pain compared to the younger 
patients. The transitional care workload appears to be 
substantial for both pediatric and adult rheumatolo-
gist in terms of improving self-efficacy, disease-fac-
tors and adjustment to future careers [31].
Educational and occupational outcomes
Gerhardt et al investigated the educational and occupa-
tional outcomes among young adults with JIA and peers
during their transition from adolescence to adulthood
[32]. Authors enrolled families when children with JIA
were 8-14 years old and each child was age-, sex-, and
race-matched with a classmate. There were 45 JIA
patients (about 12 years after diagnosis), 46 peers and
parents who completed questionnaires after the adoles-
cent's 18th birthday. Surprisingly, young adults with JIA
and peers were comparable in terms of family back-
ground, scholastic and occupational self-concept, and
academic competence. The percentage of high school
graduates and those working, those planning for further
studies or seeking employment was equivalent in both
groups [32]. Disease subtype, severity at presentation and
time elapsed were not associated with indices of educa-
tional and occupational accomplishment. This study indi-
cates that in spite of JIA and the different associated
challenges, young adults are similar to their peers as they
transition to adulthood [32].
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There is limited data on sexuality of adolescents and
young adults with JIA. A questionnaire was developed by
de Avila Lima Souza et al for the evaluation of sexuality of
male patients with JIA [33]. The authors studied a cohort
of male patients with rheumatoid factor (RF)-negative
polyarticular JIA. Thirty-two male patients with ages 16-
26 and disease duration 13-20 years had mean HAQ
score 0.1-2.1. Practice of masturbation, regular sexual
intercourse, preserved desire and satisfaction were not
significantly different between patients and controls.
However, joint pain during intercourse was more fre-
quent in patients (48% vs. 3% in controls; p < 0.001).
Increased mean HAQ score was found in the 12 patients
with joint pain during intercourse compared to the 13
patients without joint pain [33]. Further studies are
required to explore details of sexual function in a larger
sample of both male and female adolescents and young
adults with different disease subtypes.
Economic Burden
Financial costs
Arthritis and related conditions, such as juvenile arthritis,
cost the U.S. economy nearly $128 billion per year in
medical care and indirect expenses, including lost wages
and productivity [34]. Great financial burden is imposed
on families of patients with JIA and may be attributed to
the following: expensive biologic agents; frequent subspe-
cialty outpatient visits; periodic laboratory and imaging
tests; frequent visits to the pediatrician for increased URI,
etc. due to immunosuppression; physical therapy; inpa-
tient infusions and hospitalizations; and missed work
days for the parents. The process of diagnosis and treat-
ment can be very expensive [35]. Minden et al measured
direct costs (healthcare and non-healthcare costs) and
indirect costs (productivity loss due to sick leave and
work disability) in 215 JIA patients in adulthood [36].
These patients were assessed on an average of 17 years
after disease onset using clinical evaluation, a structured
interview, and two self completion questionnaires [36].
The authors assessed annual direct costs based on the
reported use of healthcare services and resources, using
average unit prices. Indirect costs were determined from
the number of work days missed-that is, using the human
capital approach. The mean total cost of late JIA was esti-
mated to be 3500 Euros per patient and year, of which the
direct cost contributed a large percentage. Ninety percent
of the cost was attributable to patients with still active
disease (55%). These patients incurred a mean total cost
of 5700 Euros per patient year, and among them those
under rheumatologic care incurred a cost of 9300 Euros.
Independent contributors to increased costing patients
with active JIA included the following variables: belong-
ing to a certain JIA subgroup, functional disability, and
receipt of specialized care. Highest mean total costs were
found in patients with active seropositive polyarthritis
(17,000 Euros) and extended oligoarthritis (11,000 Euros),
while the lowest were found in active enthesitis related
arthritis (1,500 Euros) and persistent oligoarthritis (2,700
Euros) [36]. Authors concluded that the estimated one-
year costs in are considerable and variable among the var-
ious JIA subgroups [36].
Allaire et al collected data on direct costs, family costs
and community (extra school) costs on 120 families with
children with JRA in New England, and published the
results in 1992 [3]. The mean yearly direct cost per child
was $7,905 (inpatient: $1,717; outpatient: $5,700; and
nonmedical: $488). Family costs averaged $1,524/year
(out of pocket medical and nonmedical: $1,196; lost sal-
ary: $328), which corresponded to 5% of mean family
income. The mean extra school cost was $1,449/9
months. This study shows that the economic impacts of
JRA is significant [3].
Given the fluctuating nature of the disease, the need for
treatment escalation, physical therapy, screening for oph-
thalmologic complications and surgery, cumulative costs
need to be determined. Especially with the advent of bio-
logic therapies, treatment strategies in JIA should be ana-
lyzed for their long-term cost effectiveness [36].
Ambulatory health care visits, hospitalizations, and 
mortality
The National Ambulatory Medical Care Survey and
National Hospital Ambulatory Medical Care Survey
found that among children < 17 years in 1997-98, there
was an average of 1.3 million AORC-related ambulatory
care visits per year related to arthritis and other rheu-
matic conditions (AORC) [37]. Hootman et al reported
that pediatric arthritis-related visits were more likely to
be made by girls (67%), whites (82%), non-Hispanics
(66%) and children were aged 12-17 years (59%). Most
visits occurred in physician offices (75%) compared to
outpatient departments (18%) and emergency depart-
ment (7%). The main three diseases seen were: soft tissue
disorders excluding back (41%; 513,000), unspecified
joint pain/effusion (31%; 387,000), and rheumatoid
arthritis (10%; 122,000). Among physician office visits,
41% saw family practice/general practitioners/internal
medicine; 33% saw rheumatologists/orthopedists/neurol-
ogists; and 26% saw pediatricians [37].
Sacks et al estimated the prevalence of and the annual
number of ambulatory health care visits (physician, out-
patient, emergency) for children with significant pediat-
ric arthritis and other rheumatologic conditions (SPARC)
using data from the 2001-2004 National Ambulatory
Medical Care Survey and 2001-2004 National Hospital
Ambulatory Medical Care Survey [2]. Visit estimates
were converted into prevalence estimates using data on
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estimates for states were extrapolated using national
rates. The average annualized number of children with
SPARC was 294,000 (95% confidence interval [95% CI]
188,000-400,000); and ambulatory health-care visits were
827,000 (95% CI 609,000-1,044,000) [2]. Study data also
show that children diagnosed with arthritis and other
rheumatologic conditions had an average of 83,000 emer-
gency department room visits annually [2]. With codes
for AORC as defined in adults, in 1997, among children <
14 years, there were 21,000 hospitalizations with chief
diagnosis of AORC (rate = 3.5/10,000) and 33,000 hospi-
talizations with any reference to AORC (rate = 9.2/
10,000) out of 2,266,000 childhood hospitalizations
(0.9%-1.45% of all hospitalizations)[38]. Undoubtedly, the
number of arthritis-related health care visits is significant
and impacts the families' HRQOL and burdens the pedi-
atric health care system. Detailed tracking of such data
for different subtypes of JIA is important over the long-
term [2].
Sacks et al reviewed multiple cause of death tapes from
the National Center for Health Statistics (NCHS) from
1979 to 1998. The authors found that the crude death rate
from AORC was 2.46 per 100,000 in 1979, and by 1998, it
was 3.48. The three categories of AORC that accounted
for almost 80% of deaths were diffuse connective tissue
diseases (34%), other specified rheumatic conditions
(23%), and rheumatoid arthritis (22%) [39].
Using AORC codes, the Centers for Disease Control
and Prevention's (CDC) NCHS death data revealed that
about 1,000 children younger than 15 years of age died
from arthritis and other rheumatic conditions in the 20
years from 1979-1998 (average = 50 deaths/year). The
juvenile AORC death rate fell 25% during the 20-year
period from 1.2 per million to 0.9 per million (average = 1
death per million children per year) [39] (study quoted in
the CDC website-[40]).
Hashkes et al described mortality rates, causes of death,
and potential mortality risk factors in pediatric rheumatic
diseases in the US using the Indianapolis Pediatric Rheu-
matology Disease Registry, which included 49,023
patients from 62 centers who were newly diagnosed
between 1992 and 2001[41]. Authors confirmed 110
deaths among 48,885 patients (0.23%). Patients had been
followed up for a mean ± SD of 7.9 ± 2.7 years. The stan-
dardized mortality ratios (SMR) of the entire cohort was
significantly decreased (0.65 [95% CI 0.53-0.78]), with
differences in patients followed up for > or = 9 years. The
SMR was significantly greater for systemic lupus erythe-
matosus (3.06 [95% CI 1.78-4.90]) and dermatomyositis
(2.64 [95% CI 0.86-6.17]) but not for systemic juvenile
rheumatoid arthritis (1.8 [95% CI 0.66-3.92]). Causes of
death were related to the rheumatic diagnosis (including
complications) in 39 patients (35%), treatment complica-
tions in 11 (10%), non-natural causes in 25 (23%), back-
ground disease in 23 (21%), and were unknown in 12
patients (11%). Rheumatic diagnoses, age at diagnosis,
sex, and early use of systemic steroids and methotrexate
were significantly associated with the risk of death. Their
findings showed that the overall mortality rate for pediat-
ric rheumatic diseases was not increased. Even for the
diseases and conditions associated with increased mor-
tality, mortality rates were significantly lower than those
reported in previous studies [41]. Current data are
required for patients on biologic treatments. Further, in
order to elucidate the impact on cost, hospitalizations,
ambulatory care and emergency room visits codes spe-
cific for childhood arthritis should be used and specified
for particular disease and subtype.
Conclusion
Juvenile arthritis imposes a significant burden on differ-
ent spheres of the patients', caregivers' and family's life. In
addition, it imposes a societal burden of significant health
care costs and utilization. Juvenile arthritis affects health-
related quality of life, physical function and visual out-
come of children and impacts functioning in school and
home. The extent of impact on the various aspects of the
patients', families' and society's functioning is clear from
the existing literature. Effective, well-designed and appro-
priately tailored interventions are required to minimize
the burden on costs; enhance transitioning to adult care,
improve school function and future vocation/occupation
and overall the long-term outcome of patients.
In the next two decades, some of the aspects of disease
course may significantly change with the increasing use
of biologic agents for treatment of patients with juvenile
arthritis. The impact of juvenile arthritis on the various
aspects of the patients', families' and societies' function-
ing would require re-examination at that time. Creating
and sharing world-wide prospective registries on all
patients with childhood arthritis would enable us to gar-
ner data on the burden of the disease subtypes, health
outcomes, and safety of medications, as we transition to
the era of biologic medications.
We emphasize again that the subtypes of JIA together
are very different diseases and associated with unique
complications. Despite that, we can still accurately
acknowledge that the various subtypes of JIA impose a
major physical, psychosocial and economic burden on
the patient, family and society; and currently we are in
need for appropriate interventions.
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